MiGenTra Egypt is the first R&D and manufacturing biopharmaceutical facility in Egypt, Africa, and the Middle East. It originated from a joint-venture between German based Rhein-Biotech (currently known as Dynavax Europe) and Minapharm Pharmaceuticals in 2001. MiGenTra Egypt specializes in the development and manufacturing of therapeutic recombinant proteins with a primary focus on the areas of liver disease, thrombosis and haemostasis, infertility, oncology as well as rheumatoid arthritis.

MiGenTra Egypt


MiGenTra Egypt’s mission is to be the premier biotech company in Egypt and the Middle East, through building and implementing new technologies to treat particular diseases and combat complicated epidemics.

The company pledges to provide up-to-date therapies that make a difference in the lives of millions of patients of all socio-economic levels in developing communities, and to provide a timely benefit from the latest advances in recombinant technologies.

Future plan

As a biotechnology pioneer in Egypt, MiGenTra Egypt feels responsible to support this vital field and is ready and willing to lead the successful implementation of that key technology in the region for the collective good of the public health system. Therefore, near future plans and endeavors include MiGenTra Egypt biotech division growing constantly and exponentially. This continuous extension of existing in-house technologies, yeast as well as mammalian expression systems, is a milestone towards success. Through its strong product pipeline MiGenTra Egypt Biogenetics will continue to assure and strengthen its role as a leader in the production of innovative recombinant proteins in the region.

Minapharm, jointly with its subsidiaries, MiGenTra Egypt and ProBioGen AG, has the visionary strategy to evolve and to introduce cutting-edge immunotherapies to emerging markets with its high scientific competence and expertise. The synergy projects between Minapharm and its subsidiaries allow the company to offer life-saving and life-enhancing medications, which are normally very expensive, at affordable prices as they are manufactured straight from the cell to the finished product.